Literature DB >> 31464743

Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.

Zobair M Younossi1,2, Maria Stepanova3, Eric J Lawitz4, K Rajender Reddy5, Vincent Wai-Sun Wong6, Alessandra Mangia7, Andrew J Muir8, Ira Jacobson9, C Stephen Djedjos10, Anuj Gaggar10, Robert P Myers10, Issah Younossi3, Fatema Nader3, Andrei Racila3.   

Abstract

INTRODUCTION: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully assessed. The aim is to compare HRQL scores in patients with CHC to those with NASH.
METHODS: Matched patients with advanced fibrosis (bridging fibrosis and compensated cirrhosis) due to CHC and NASH completed Short Form-36 (SF-36) questionnaire, Chronic Liver Disease Questionnaire (CLDQ), and Work Productivity and Activity Instrument questionnaire.
RESULTS: We included 1,338 patients with NASH with advanced fibrosis (mean age 57.2 years, 47% men, 55% cirrhosis) and 1,338 matched patients with CHC. Patients with CHC and NASH had similar rates of employment and psychiatric disorders (P > 0.05). As expected, patients with NASH had higher body mass index (mean 33.7 vs 27.6) and more type 2 diabetes (74% vs 16%) (all P < 0.01). Patients with NASH had significantly lower HRQL scores related to physical health: Physical Functioning, Bodily Pain, General Health, Vitality, Physical Summary of SF-36, and Fatigue of CLDQ (P < 0.02). By contrast, patients with CHC had a lower Mental Health score of SF-36 and Emotional score of CLDQ and reported greater impairment in daily activities as measured by the Work Productivity and Activity Instrument questionnaire (P < 0.002). In multivariate analysis, after adjustment for demographic parameters, cirrhosis, and history of psychiatric disorders, having NASH was associated with lower physical HRQL scores and higher mental health-related scores (P < 0.05). DISCUSSION: Patients with NASH and advanced fibrosis have more impairment of their physical health-related scores than patients with CHC with advanced fibrosis. These data should dispel the misconception that NASH is an asymptomatic disease with little negative impact on patients' well-being.

Entities:  

Year:  2019        PMID: 31464743     DOI: 10.14309/ajg.0000000000000375

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review.

Authors:  Huimin Zou; Ying Ge; Qing Lei; Carolina Oi Lam Ung; Zhen Ruan; Yunfeng Lai; Dongning Yao; Hao Hu
Journal:  Hepatol Int       Date:  2022-01-31       Impact factor: 6.047

Review 2.  Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.

Authors:  Ashley Vander Does; Cynthia Levy; Gil Yosipovitch
Journal:  Am J Clin Dermatol       Date:  2022-07-28       Impact factor: 6.233

3.  IL-6 and IL-10 gene polymorphisms and cirrhosis of liver risk from a comprehensive analysis.

Authors:  Minghui Zheng; Weizhen Fang; Menglei Yu; Rui Ding; Hua Zeng; Yan Huang; Yuanyang Mi; Chaohui Duan
Journal:  BMC Endocr Disord       Date:  2021-12-09       Impact factor: 2.763

4.  The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.

Authors:  Zobair Younossi; Priya Aggarwal; Ichhya Shrestha; João Fernandes; Pierre Johansen; Margarida Augusto; Sunita Nair
Journal:  JHEP Rep       Date:  2022-06-15

5.  Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.

Authors:  Zobair M Younossi; Maria Stepanova; Mazen Noureddin; Kris V Kowdley; Simone I Strasser; Anita Kohli; Peter Ruane; Mitchell L Shiffman; Aasim Sheikh; Nadege Gunn; Stephen H Caldwell; Ryan S Huss; Robert P Myers; Vincent Wai-Sun Wong; Naim Alkhouri; Zachary Goodman; Rohit Loomba
Journal:  Hepatol Commun       Date:  2021-05-12

Review 6.  Management of nonalcoholic fatty liver disease in the Middle East.

Authors:  Faisal M Sanai; Faisal Abaalkhail; Fuad Hasan; Muhammad Hamed Farooqi; Nawal Al Nahdi; Zobair M Younossi
Journal:  World J Gastroenterol       Date:  2020-07-07       Impact factor: 5.742

7.  Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.

Authors:  Manuel Romero-Gomez; Nandita Kachru; Meritxell Ascanio Zamorano; Josep Darba; Sanatan Shreay
Journal:  Medicine (Baltimore)       Date:  2020-12-11       Impact factor: 1.817

8.  The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population.

Authors:  Wenhao Li; Benjamin Karl Kadler; James Hallimond Brindley; Gillian Hood; Kalpana Devalia; John Loy; Wing-Kin Syn; William Alazawi
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.